Targeting α-synuclein oligomers by protein-fragment complementation for drug discovery in synucleinopathies

The application of the strategy described herein to monitor α-synuclein oligomer formation in living cells with high throughput will facilitate drug discovery efforts for disease-modifying therapies against synucleinopathies and other proteinopathies.